Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,680 Cr
verified against source
Revenue YoY
8%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fortis Healthcare reported a satisfactory Q3 FY24 with consolidated revenue of INR 1,680 crore (+8% YoY) and operating EBITDA margin of 16.9% (down 80bps YoY). Hospital business revenue grew 10% YoY to INR 1,389 crore, with EBITDA margin expanding to 18% (+130bps YoY) driven by cost optimization and a shift to high-complexity procedures. ARPOB grew 10.6% YoY to INR 2.23 crore. Occupancy dipped to 64% due to seasonal factors and bed additions, but management expects recovery to ~70% in Q4. Brownfield expansion of ~2,200 beds over four years and divestment of loss-making Chennai facilities support margin trajectory toward 20% by year-end and 25% over 3-4 years. Key risk: slower-than-expected ramp-up of new beds and occupancy, which could delay margin expansion.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
- Over the next 3-4 years, as brownfield bed expansions ramp up, management aims for 25% EBITDA margin.
- Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
- Management expects occupancy to recover to ~70% in Q4 FY24 and next year, driven by seasonal recovery and international patient rebound.
Risks flagged
- New bed additions could dilute occupancy, delaying margin expansion. Management acknowledged this but expects gradual ramp-up.
- Flat international revenue in Q3 due to Middle East tensions; recovery seen but risks remain from geopolitical instability.
- ~950 beds in hospitals with <10% EBITDA margin; structural improvements like adding specialties will take 2-3 years.
- FMRI Gurgaon saw a premium cardiac clinician depart, impacting Q3 performance. New clinician expected to join in Q4.
Key quotes
- Our business performance in Q3 has been satisfactory considering the seasonal impact of festivals in some of our key geographies.
- We are maintaining our margin guidance, that slowly, as we know, this ramp up will happen with the bed expansion. By next three to four years, we should be aiming towards 25%.
- The price increase is mainly attributable toward the specialty mix change and the type of procedures we are doing, which is the high-end procedures.
Research modules